Clinical trial · Observational
Targeting Inflammation for Endometrial Cancer Prevention
NCT05407025CI-TRIAL-00099354active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Carcinoma | Endometrial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational (questionnaire, biospecimen collection)
- description
- Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.
- interventionNames
- Procedure: Biospecimen Collection
- Other: Questionnaire Administration
Primary outcomes (1)
- measure
- Levels of eicosanoids and specialized pro-resolving mediators (SPMs) in visceral adipose tissue (VAT)
- timeFrame
- Through study completion, up to 24 weeks
- description
- Will compare eicosanoid and SPM levels by case-control status (women with endometrial carcinoma and women with non-cancerous conditions) in all patients with linear models, adjusted for age and body mass index (BMI) (and menstrual date, if needed).
Secondary outcomes (1)
- measure
- Ribonucleic acid (RNA) expression pathways related to inflammation in VAT
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women over the age of 18 years old undergoing hysterectomy for any benign indication or endometrial cancer Exclusion Criteria: * Men * Women under the age of 18 years * Women with a history of cancer, except for endometrial cancer or non-melanoma skin cancer * Women with type 1 diabetes * Women that have received radiation or chemotherapy for cancer
References
Publications (0)
Data not yet available
No reference posted for this study.